Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint
Study: Rencarex Treatment Efficacy Increases With CAIX Antigen Density in Tumor Tissue
DSMB Recommends Discontinuing Phase III Perifosine Combination Trial
51% Control Rate Achieved In Phase II Trial of Elderly Patients
Study: Partial Kidney Removal Leads to Greater Survival
Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint
AIDS Cachexia Drug Stabilizes Body Weight, Muscle Mass
Two Children Achieve Remission With CD19 Immunotherapy
Adjuvant Chemotherapy Unneeded In Children with Low-Risk Disease
Study: Oncotype DX Score Can Predict Local Recurrence
BRAF Mutation Testing Classifies Indeterminate FNA Samples
NCI CTEP Approved Trials For the Month of March
FDA Approves Lymphoseek For Imaging Lymph Nodes
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - George Sigounas named the first-ever chief science advisor at NCI
- In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”
- Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State
- Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response
